全球经前综合症治疗市场 - 2022-2029

市场动态

全球经前综合征治疗市场的推动力来自于全球对经前综合征治疗重要性的认识不断提高、政府和非政府组织加大力度解决女性保健问题以及开发新的治疗方法。几个因素。

预计庞大的目标人群和新治疗方法的开发将成为市场增长的驱动力。

由于它是育龄妇女最常见的健康问题，庞大的目标人群推动了市场。 Petranka Chumpalova 等人在 2020 年发表在《普通精神病学年鑑》上的一项研究发现，90% 的育龄妇女会出现从轻微到严重的经前综合征症状。经证实，其中约 20-40% 的人患有经前综合症，其中约 2-8% 的人患有经前烦躁症 (PMDD)。

开发经前综合症治疗方法的研发活动预计将对市场产生积极影响。例如，与安慰剂相比，通过 PRN 鼻内给药的 PH80-PMD（Ferrin Pharma）在关键的经前期表现出中度至重度经前期综合征症状，而无需长期给药。临床试验表明，它显着降低

Asalina Pharma 正在开发一种很有前景的产品，用于治疗痛经 (PMDD)，这是一种严重的致残性经前期综合征。该公司的旗舰产品 Cepranolon 在一项针对 120 名经前焦虑症女性的新 II 期研究中达到了主要安全性和有效性终点。 Sepraolone 是一种一流的内源性小分子化合物，可作为 GABA-A 调节类固醇拮抗剂 (GAMSA)。

全世界对经前综合症诊断、治疗和医疗费用的认识正在提高。例如，2019年6月，经前烦躁症（PMDD）被赋予了独特的分类代码，并在WHO新的国际疾病分类ICD-11中首次明确将其归类为妇科疾病而非精神疾病。我是。将 PMDD 纳入 ICD-11 是一个重要指标，表明全球对 PMDD 的医学意识不断提高，科学界越来越一致认为 PMDD 是一种激素而不是精神疾病。世界卫生组织目前的 ICD-10 也提到了 PMDD，但间接地作为“经前紧张综合征”的一个子类。

与使用治疗剂相关的副作用预计会阻碍市场增长。

但是，与使用经前期综合征药物相关的副作用可能会阻碍市场增长。例如，使用选择性 5-羟色胺再摄取抑製剂 (SSRI) 会导致噁心、虚弱、疲劳、性功能障碍和精力不足等不良事件。不建议长期使用促性腺激素释放激素 (GnRH) 类似物，因为它们会对骨密度产生不利影响并增加发生骨变薄的风险。

行业分析

全球经前综合症治疗市场根据波特五力、监管分析、供应链分析和定价分析等各种行业因素对市场进行了深入分析。

全球经前综合症治疗市场报告提供了大约 45 多个市场数据表、40 多个数字和 180 页的组成。

内容

第一章研究方法与范围

• 调查方法
• 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

• 市场影响因素
  • 驱动程序
    • 扩大目标人群
    • 治疗方法的开发
  • 约束因素
    • 抑制因素：与使用治疗剂相关的副作用
  • 商机
  • 影响分析

第五章行业分析

• 波特五力分析
• 监管分析
• 供应链分析
• 定价分析

第 6 章按药物类别

• 止痛药
• 抗抑郁药
• 口服避孕药
• 卵巢抑製剂
• 促性腺激素释放激素 (GnRH) 类似物
• 仅含雌激素的贴片和植入物
• 选择性血清素再摄取抑製剂 (SSRI)
• 其他

第 7 章按销售渠道

• 医院药房
• 药店和零售药店
• 在线提供商
• 其他

第 8 章按地区

• 北美
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 意大利
  • 西班牙
  • 其他欧洲
• 南美洲
  • 巴西
  • 阿根廷
  • 其他南美洲
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 其他亚太地区
• 中东和非洲

第 9 章竞争格局

• 主要发展和战略
• 公司份额分析
• 治疗分类基准
• 值得关注的重点公司列表

第 10 章公司简介

• Bayer AG
  • 公司概况
  • 药物类别组合和说明
  • 主要亮点
  • 财务摘要
• Eli Lilly And Company
• GlaxoSmithKline Plc.
• H. Lundbeck A/S
• Pfizer Inc.
• Asarina Pharma AB
• Chattem, Inc.（Sanofi）
• Dekk-Tec
• Pherin Pharmaceuticals
• Novartis International AG

第 11 章全球经前综合征治疗市场-DataM

Market Overview

Premenstrual Syndrome Treatment Market size was valued US$ 1,367 million in 2021 and is estimated to reach US$ 1,829 million by 2029, growing at a CAGR of 4.1% during the forecast period (2022-2029).

Premenstrual Syndrome is a combination of physical and emotional symptoms, including mood swings, body pain, fatigue, tender breasts, food cravings, fatigue, irritability, and depression. It arises around the end of the luteal phase and dissipates with menstruation or briefly thereafter. It is most commonly observed among women with a high level of stress, depression, cyclic changes in the menstruation cycle, and chemical changes in the brain.

Market Dynamics

The global premenstrual syndrome treatment market is growing due to several factors such as growing awareness towards the significance of premenstrual syndrome treatment globally and rising government and non-government organizations initiatives doe women healthcare and various developments of new therapies.

Larger targeted population and new developments in therapies are expected to drive market growth.

The larger targeted population drives the market as it is the most common health problem in women of reproductive age. According to Petranka Chumpalova et al. 2020, in a study published in the Annals of General Psychiatry journal, 90% of women of reproductive age experience several premenstrual symptoms varying from mild to severe. Approximately 20-40% of those women suffer from Premenstrual Syndrome, and around 2-8% of those women suffer from the premenstrual dysphoric disorder (PMDD) worldwide.

The undergoing research and development activities to develop therapies for Premenstrual Syndrome shall positively impact the market. For instance, the clinical studies demonstrated that the administration of the PH80-PMD (Pherin Pharmaceuticals) administered intranasally PRN decreased moderate and severe premenstrual symptoms significantly better compared to the placebo during the critical premenstrual days of the cycle without the need for chronic administration.

Asarina Pharma is developing a potential therapy for the treatment of Premenstrual Dysphoric Disorder (PMDD), a severe and disabling form of premenstrual syndrome. Its lead product, i.e., Sepranolone, had met its primary safety and efficacy endpoints in a new Phase II study involving 120 women with Premenstrual Dysphoric Disorder. Sepranolone is a proprietary, first-in-class, endogenous, small molecule that acts as a GABA-A modulating steroid antagonist (GAMSA).

There is an increase in awareness regarding the diagnosis, treatment, and reimbursement of premenstrual syndrome worldwide. For instance, in June 2019, Premenstrual dysphoric disorder (PMDD) has been given its own classification code and, for the first time, classified clearly as a gynecological, not mental, disease in the WHO's new International Classification of Diseases, ICD-11. The inclusion of PMDD in ICD-11 is an important indicator of the growing medical awareness of PMDD worldwide and a growing scientific consensus that PMDD is a hormonal, not psychiatric condition. PMDD is mentioned in the WHO's present ICD-10, but indirectly as a sub-classification under 'Premenstrual tension syndrome.

Side-effects associated with use of therapies are expected to hamper the market growth.

However, the side-effects associated with the use of therapies for premenstrual syndrome shall hider market growth. For instance, the use of selective serotonin reuptake inhibitors (SSRIs) results in adverse events such as nausea, asthenia, fatigue, sexual dysfunction, and decreased energy. Gonadotropin-releasing hormones (GnRH) analogs are not recommended for the long term as these analogs lead to adverse effects on bone density and increase the risk of developing bone thinning.

Industry Analysis

The global premenstrual syndrome treatment market provides in-depth analysis of the market based on various industry factors such as Porter's Five Forces, Regulatory Analysis, Supply Chain Analysis, Pricing Analysis.

Segment Analysis

Product type segment is expected to hold the largest market share in global premenstrual syndrome treatment market

The premenstrual syndrome treatment market is segmented based on product type as analgesics, antidepressants, oral contraceptives agents, ovarian suppression agents, gonadotropin-releasing hormone (GnRH) analogs, estrogen-only patches & implants, selective serotonin reuptake inhibitors (SSRIs), and others. The analgesics segment accounts for the highest market share owing to the higher uptake of analgesics as it is the mainstay treatment for premenstrual syndrome. Various analgesics such as ibuprofen, acetaminophen, diclofenac, naproxen is used for the management of premenstrual syndrome. These analgesics are effective in reducing stomach cramps, headache, muscle pain, joint pain and others.

The oral contraceptive agent segment is expected to have positive market growth due to the rising usage of oral contraceptive agents to manage the physical and psychiatric symptoms of premenstrual syndrome. The oral contraceptive agents, including the levonorgestrel/ Ethinyl estradiol, drospirenone and others, are used to even out the ovarian hormone fluctuations. Clinical studies have demonstrated that the administration of 90 mcg levonorgestrel/20 mcg Ethinyl estradiol resulted in improvement in depressive and physical symptoms.

The antidepressant segments account for the significant market share over the forecasted period. The antidepressants act by increasing the brain chemicals, including opioids, serotonin, and others hampered due to the ovarian hormones. Serotonin reuptake inhibitors (SSRIs) are recommended for treating the mood changes associated with Premenstrual Syndrome. The market is dominated by the availability of several serotonin reuptake inhibitors, including Fluoxetine (Prozac), paroxetine (Paxil), Sertraline (Zoloft), citalopram (Celexa) and escitalopram (Lexapro) for the treatment of psychiatric symptoms associated with Premenstrual Syndrome. The clinical studies demonstrated that these five serotonin reuptake inhibitors (SSRIs) have statistically significant benefits on patient-reported symptoms when taken continuously or only during the luteal phase.

Further, the market is also classified based on distribution channel as hospital pharmacies, drug stores & retail pharmacies, online providers, and others. The drug stores & retail pharmacies segment are expected to have the highest market share due to many drug stores & retail pharmacies worldwide. The majority of the drugs being used for the premenstrual syndrome are the counter drugs, which are easily available over the counter without a prescription. It is further expected that the drug stores & retail pharmacies segment shall lose its market share with the rising growth of online providers worldwide over the forecasted period.

The online provider's segment is expected to have significant market growth due to the growing preference for online purchasing of drugs compared to the traditional methods, including the drug stores & retail pharmacies and hospital pharmacies. The rising awareness regarding online providers, growing internet users, and digital transformation shall stimulate market growth. Hence, it is expected that online providers shall account for the highest market share over the forecasted period.

Geographical Analysis

North America region holds the largest market share in the global premenstrual syndrome treatment market

By region, the premenstrual syndrome treatment market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all of the regions, North America dominated the premenstrual syndrome treatment market due to the rising prevalence of premenstrual syndrome. According to the American Academy of Family Physicians, in 2020 approximately 90% of childbearing age women experience premenstrual symptoms, and less than 10% are diagnosed with the premenstrual dysphoric disorder (PMDD). The growing awareness regarding women's health shall stimulate market growth. For instance, The Office on Women's Health (OWH) within the U.S. Department of Health and Human Services (HHS) is involved in creating awareness by addressing the critical women's health issues. It helps inform and advance policies, educate professionals and consumers, and support programs related to women's health, including the premenstrual syndrome.

The Asia-Pacific is expected to have positive market growth due to many females of childbearing age. There are growing government initiatives and campaigns for improving women and maternity health. For instance, India's National Health Portal creates awareness of women's health issues, including premenstrual syndrome. The rising expenditure for improving the healthcare facilities and infrastructure shall have a positive impact on the market. Substantial market growth is expected to be observed in developing countries, including India & China.

Competitive Landscape

Bayer AG, Eli Lilly and Company, GlaxoSmithKline Plc, Pfizer Inc., H. Lundbeck A/S, Pfizer Inc., Asarina Pharma AB, Chattem, Inc. (Sanofi), Dekk-Tec, Pherin Pharmaceuticals, Novartis International AG are the leading market players with significant market share. The new product development, opportunity, and revenue generation shall intensify the market competition.

The companies use strategies such as collaborations, mergers, strategic partnerships, and acquisitions to hold their positions in the market. For instance, In Aug 2020, Bayer's acquired KaNDy Therapeutics Limited to boost their female healthcare business.

Key Companies to Watch

Bayer AG:

Overview: Bayer is a biotech and pharmaceutical multinational company. It was founded in 1863 and is headquartered in Leverkusen, Germany. Their business area includes pharmaceutical, agriculture chemicals, healthcare products and biotechnology products.

Product Portfolio:

vissane: It is a progestin medication that is generally used in birth control pills and is used to treat heavy periods and for menopausal hormone.

Key Developments: In Aug 2020, Bayer's acquired KaNDy Therapeutics Limited to boost their female healthcare business.

The global premenstrual syndrome treatment market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers:
    • 4.1.1.1. Larger targeted population
    • 4.1.1.2. Development of therapies
  • 4.1.2. Restraints:
    • 4.1.2.1. Side-effects associated with the use of therapies
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Regulatory Analysis
• 5.3. Supply Chain Analysis
• 5.4. Pricing Analysis

6. By Drug Class

• 6.1. Introduction
  • 6.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Segment
  • 6.1.2. Market Attractiveness Index, By Drug Class Segment
• 6.2. Analgesics
  • 6.2.1.1. Introduction
  • 6.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 6.3. Antidepressants
• 6.4. Oral Contraceptives
• 6.5. Ovarian Suppression Agents
• 6.6. Gonadotropin-releasing hormone (GnRH) Analogues
• 6.7. Estrogen-only patches & implants
• 6.8. Selective serotonin reuptake inhibitors (SSRIs)
• 6.9. Others

7. By Distribution Channel

• 7.1. Introduction
  • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
  • 7.1.2. Market Attractiveness Index, By Distribution Channel Segment
• 7.2. Hospital Pharmacies
  • 7.2.1.1. Introduction
  • 7.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 7.3. Drug Stores and Retail Pharmacies
• 7.4. Online providers
• 7.5. Others

8. By Region

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 8.1.2. Market Attractiveness Index, By Region
• 8.2. North America
  • 8.2.1. Introduction
  • 8.2.2. Key Region-Specific Dynamics
  • 8.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 8.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 8.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 8.2.5.1. U.S.
    • 8.2.5.2. Canada
    • 8.2.5.3. Mexico
• 8.3. Europe
  • 8.3.1. Introduction
  • 8.3.2. Key Region-Specific Dynamics
  • 8.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 8.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 8.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 8.3.5.1. Germany
    • 8.3.5.2. U.K.
    • 8.3.5.3. France
    • 8.3.5.4. Italy
    • 8.3.5.5. Spain
    • 8.3.5.6. Rest of Europe
• 8.4. South America
  • 8.4.1. Introduction
  • 8.4.2. Key Region-Specific Dynamics
  • 8.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 8.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 8.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 8.4.5.1. Brazil
    • 8.4.5.2. Argentina
    • 8.4.5.3. Rest of South America
• 8.5. Asia Pacific
  • 8.5.1. Introduction
  • 8.5.2. Key Region-Specific Dynamics
  • 8.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 8.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 8.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 8.5.5.1. China
    • 8.5.5.2. India
    • 8.5.5.3. Japan
    • 8.5.5.4. Australia
    • 8.5.5.5. Rest of Asia Pacific
• 8.6. Middle East and Africa
  • 8.6.1. Introduction
  • 8.6.2. Key Region-Specific Dynamics
  • 8.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 8.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

9. Competitive Landscape

• 9.1. Key Developments and Strategies
• 9.2. Company Share Analysis
• 9.3. Drug Classs Benchmarking
• 9.4. List of Key Companies to Watch

10. Company Profiles

• 10.1. Bayer AG
  • 10.1.1. Company Overview
  • 10.1.2. Drug Class Portfolio and Description
  • 10.1.3. Key Highlights
  • 10.1.4. Financial Overview
• 10.2. Eli Lilly And Company
• 10.3. GlaxoSmithKline Plc.
• 10.4. H. Lundbeck A/S
• 10.5. Pfizer Inc.
• 10.6. Asarina Pharma AB
• 10.7. Chattem, Inc. (Sanofi)
• 10.8. Dekk-Tec
• 10.9. Pherin Pharmaceuticals
• 10.10. Novartis International AG

LIST NOT EXHAUSTIVE

11. Global Premenstrual Syndrome Treatment Market - DataM

• 11.1. Appendix
• 11.2. About Us and End User
• 11.3. Contact Us